Xiying Shao

No.1 Banshan East Road, Gongshu District
Hangzhou, 310022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication.

Axitinib promotes stemness and vasculogenic mimicry in triple-negative breast cancer by disrupting THBS1-CD47 axis-mediated endothelial-tumor cell communication.

Journal: Apoptosis : an international journal on programmed cell death

Published: March 13, 2026

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial.

Journal: Nature medicine

Published: February 05, 2026

Synergistic Anti-Tumor Activity of LRPPRC Inhibition and Dasatinib Through Dual Oxidative Phosphorylation Disruption.

Synergistic Anti-Tumor Activity of LRPPRC Inhibition and Dasatinib Through Dual Oxidative Phosphorylation Disruption.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: January 28, 2026

Electroacupuncture frequency for chemotherapy-induced neuropathy in breast cancer: a randomized controlled trial.

Electroacupuncture frequency for chemotherapy-induced neuropathy in breast cancer: a randomized controlled trial.

Journal: The oncologist

Published: June 02, 2025

Effects of Electroacupuncture and Mecobalamin for Utidelon-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Clinical Trial.

Effects of Electroacupuncture and Mecobalamin for Utidelon-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Clinical Trial.

Journal: Journal of pain research

Published: March 05, 2025

A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells.

A signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: January 09, 2025

Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.

Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial.

Journal: Journal of translational internal medicine

Published: November 08, 2024

Electroacupuncture with different frequencies for paclitaxel-induced peripheral neuropathy: a randomized controlled trial

Electroacupuncture with different frequencies for paclitaxel-induced peripheral neuropathy: a randomized controlled trial

Journal: Zhongguo zhen jiu = Chinese acupuncture & moxibustion

Published: October 14, 2024

LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a therapeutic target.

LRPPRC confers enhanced oxidative phosphorylation metabolism in triple-negative breast cancer and represents a therapeutic target.

Journal: Journal of translational medicine

Published: August 05, 2024

Global, reginal, national burden and risk factors in female breast cancer from 1990 to 2021.

Global, reginal, national burden and risk factors in female breast cancer from 1990 to 2021.

Journal: iScience

Published: July 03, 2024

Proteomic and metabolomic characterization of bone, liver, and lung metastases in plasma of breast cancer patients.

Proteomic and metabolomic characterization of bone, liver, and lung metastases in plasma of breast cancer patients.

Journal: Proteomics. Clinical applications

Published: November 13, 2023

Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.

Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.

Journal: Cancer

Published: September 09, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026